Last reviewed · How we verify
hypoglycemic therapy
At a glance
| Generic name | hypoglycemic therapy |
|---|---|
| Also known as | metformin |
| Sponsor | Research Institute for Complex Problems of Cardiovascular Diseases, Russia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Vascular Complications in Patients Undergoing Peripheral Revascularization and Taking SGLT-2 Inhibitors
- SGLT2i Improve Left Atrial Function in Patients With Paroxysmal Atrial Fibrillation, Hypertension and Abnormal Glucose Metabolism (PHASE2)
- Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT) (NA)
- The Use of Advanced Imaging in HFpEF
- iGlarLixi CGM Study in Chinese T2D Individuals After OADs (PHASE4)
- Safety and Effectiveness of Overripe Banana Powder Added to Diabetic Formulas in Type 2 Diabetes (NA)
- Impact of Date Consumption on Metabolic Control and Oxidative Stress in Patients With Type 2 Diabetes (NA)
- Early Add-On Combination of GLP-1 Receptor Agonist and SGLT2 Inhibitor in People With Cardiovascular-Kidney-Metabolic Stage 2-3
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: